Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Solid Tumor : Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue cancer in children and adolescents. Participants in this research study have tumors that are considered an intermediate risk tumor. The term “risk” refers to the chance of the cancer coming back after treatment. Results from past studies indicate there is about a 35 percent chance that the tumor will return after treatment.
The normal treatment for intermediate-risk rhabdomyosarcoma is surgery, anti-cancer drug therapy (chemotherapy), and radiation therapy (treatment with high energy x-rays). The standard chemotherapy includes vincristine, dactinomycin and cyclophosphamide (known as VAC).
In this research study doctors want to determine if adding an additional drug combination will improve the outcome for the participants. This drug combination is vincristine plus irinotecan and is referred to as VI. The doctors will also look at the effectiveness of giving radiation therapy earlier in the treatment schedule. The study will also evaluate if a lower dose of cyclophosphamide is as effective in treating RMS, but with fewer bad effects during and after treatment.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Sheri Spunt, MD
St. Jude Children’s Research Hospital
332 N. Lauderdale
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.